| Revision as of 03:49, 12 September 2020 editCitation bot (talk | contribs)Bots5,433,932 edits Add: s2cid. | You can use this bot yourself. Report bugs here. | Suggested by Abductive | Category:Chemicals that do not have a ChemSpider ID assigned | via #UCB_Category← Previous edit | Revision as of 00:08, 15 June 2023 edit undoEntranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers173,243 edits Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound"Tag: Shortdesc helperNext edit → | ||
| Line 1: | Line 1: | ||
| {{Short description|Monoclonal antibody}} | |||
| {{Drugbox | {{Drugbox | ||
| | Verifiedfields = changed | | Verifiedfields = changed | ||
Revision as of 00:08, 15 June 2023
Monoclonal antibody Pharmaceutical compound| Monoclonal antibody | |
|---|---|
| Type | F(ab')2 fragment |
| Source | Mouse |
| Target | TNFα |
| Clinical data | |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| (what is this?) (verify) | |
Afelimomab (MAK 195F) is an anti-TNFα monoclonal antibody. Administration of afelimomab reduces the concentration of interleukin-6 in patients with sepsis, but reduces mortality only marginally.
References
- Rondon E, Venkataraman R (August 2005). "Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels". Critical Care. 9 (5): E20. doi:10.1186/cc3798. PMC 1297624. PMID 16277704.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, et al. (November 2004). "Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels". Critical Care Medicine. 32 (11): 2173–82. doi:10.1097/01.CCM.0000145229.59014.6C. PMID 15640628. S2CID 23321488.
| Immunosuppressive drugs / Immunosuppressants (L04) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (initiation) |
| ||||||||||||||
| Intracellular (reception) |
| ||||||||||||||
| Extracellular |
| ||||||||||||||
| Unsorted |
| ||||||||||||||
 | This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |